NCT06958107Recruiting
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy and Spectroscopy-based Molecular Urinalysis in Sarcoma Patients
Prospective Clinical Evaluation of Circulating Tumor DNA Liquid Biopsy and Spectroscopy-based Molecular Urinalysis in Patients With Sarcoma
Source: ClinicalTrials.gov · Last updated 21 Oct 2026
Brief summary (registry, in English)
The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer). This study is also looking at a new technology called Rametrix® Molecular urinalysis (RMU). The study is using this technology to evaluate changes in the urine that may indicate the presence of disease or cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 27 Apr 2025
- Start date
- 21 Aug 2025
- Primary completion date
- Jan 2030
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Childhood cancers, Sarcoma
- NCT number
- NCT06958107
What you commit to
- Study type: Observational
- Planned participants: 300
- From 21 Aug 2025 to the primary completion date, Jan 2030
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- none
Who the study is looking for
- Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information.
- All ages allowed
- Suspected or confirmed disease (must meet one of the criteria below):
- Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis)
- OR
- Suspected lipomatous mass concerning for ALT or WDLS with planned surgery
- OR
- Confirmed bone or soft tissue sarcoma meeting one of the criteria below:
- Non-metastatic/Resectable sarcoma with either planned or currently receiving therapy
- Metastatic or unresectable sarcoma, with planned or currently receiving therapy
- Non-metastatic sarcoma under surveillance with no more than 1 year from completion of therapy
Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Levine Cancer Institute Coordinator of this site? Confirm its status | Charlotte | United States | Recruiting |
| Atrium Health Wake Forest Baptist Comprehensive Cancer Center Coordinator of this site? Confirm its status | Winston-Salem | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.